


HALF-YEAR FINANCIAL REPORT H1|2025
January 1 to June 30, 2025




MISSION STATEMENT

Together with our partners, we improve quality of life. We do this by leveraging our expertise, technology, and collaborative approach to develop innovative, purpose-built solutions for leading companies in in-vitro diagnostics and adjacent markets.

As a leading OEM partner, we share responsibility for the entire product life cycle: from initial design through development, regulatory approval, production, product expansion, and ongoing support.

Our success is based on the talent and dedication of our employees and our commitment to drive innovation forward.



CONTENTS

Current Information / Key Figures | 4

Interim Group Management Report | 5

Consolidated Balance Sheet as of June 30, 2025 | 10

Consolidated Statement of Comprehensive Income
for the period from January 1 to June 30, 2025 | 12

Consolidated Statement of Cash Flows
for the period from January 1 to June 30, 2025 | 13

Consolidated Statement of Changes in Equity
for the period from January 1 to June 30, 2025 | 14

Selected Explanatory Notes
for the period from January 1 to June 30, 2025 | 16

Further Information | 26

CURRENT INFORMATION

- Consolidated sales at constant currency grow 5.8% to € 118.6 million in H1/2025 (H1/2024: € 112.7 million)
- Gross margin remains stable, but currency items lower adjusted EBIT margin to 7.2% in H1/2025 (H1/2024: 8.8%)
- Significant revival in deal pipeline in the area of system development
- 2025 guidance confirmed: sales at constant currency expected to show growth in a low to medium single-digit percentage range with adjusted EBIT margin of around 10.0% to 12.0%

KEY FIGURES¹

€ 000s	H1/2025	H1/2024 ²	Change	Q2/2025	Q2/2024 ²	Change
Sales	118,590	112,691	+5.2% (cc: +5.8%)	58,227	58,803	-1.0% (cc: +0.9%)
Adjusted EBITDA	16,070	17,426	-7.8%	6,765	10,834	-37.6%
Adjusted EBITDA margin (%)	13.6	15.5	-190 bps	11.6	18.4	-680 bps
Adjusted EBIT	8,487	9,880	-14.1%	3,124	6,960	-55.1%
Adjusted EBIT margin (%)	7.2	8.8	-160 bps	5.4	11.8	-640 bps
Adjusted consolidated net income	4,978	5,603	-11.2%	1,823	4,539	-59.8%
Adjusted earnings per share (€)	0.41	0.46	-10.9%	0.15	0.37	-59.5%
Earnings per share (€)	0.21	0.33	-36.4%	0.09	0.31	-71.0%

bps = basis points

cc = constant currency

¹ To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses).

² Restated pursuant to IAS 8.

€ 000s	06.30.2025	12.31.2024	Change
Equity	236,698	242,533	-2.4%
Total assets	422,408	445,058	-5.1%
Equity ratio (%)	56.0	54.5	+150 bps

bps = basis points

INTERIM GROUP MANAGEMENT REPORT

Report on earnings, financial, and asset position

Earnings position

STRATEC increased its consolidated sales year-on-year by 5.8% on a constant-currency basis (nominal: 5.2%) to € 118.6 million in the first half of 2025 (H1/2024: € 112.7 million). At € 34.9 million, Systems sales fell slightly short of the previous year's figure (H1/2024: € 35.8 million). This reflects the fact that start-up curves for new product launches remain flatter than usual. For molecular diagnostics systems, by contrast, which had witnessed disruptions to demand in the wake of the COVID-19 pandemic, the stabilization in demand continued. Given rising test volumes and the associated higher level of laboratory capacity utilization rates, sales with Service Parts and Consumables increased to € 53.7 million, corresponding to constant-currency growth of 3.4% (nominal: 2.8%) on the previous year's already high figure (H1/2024: € 52.3 million). Driven by a high volume of development activity for new customer projects, the Development and Services division reported significant sales growth of 20.5% on a constant-currency basis (nominal: 19.9%) to € 28.8 million (H1/2024: € 24.0 million).

Gross profit (gross profit on sales) rose from € 30.5 million to € 32.0 million in the first half of 2025. At 26.9%, the associated gross margin for the first half of 2025 almost matched the previous year's figure of 27.1%.

In view of the ongoing high volume of development activity, investments in research and development (gross development expenses) grew from € 28.1 million in the previous year to € 29.0 million in the first six months of 2025. Of this total, € 5.4 million (H1/2024: € 5.6 million) involved expenses not meeting the criteria for capitalization pursuant to IAS 38 (Intangible Assets).

Sales-related expenses decreased from € 6.9 million in the previous year to € 6.5 million in the first half of 2025.

General administration expenses rose from € 11.3 million in the previous year to € 13.0 million in the first half of 2025, with this increase being due among other factors to higher advisory expenses and fees.

The net balance of income and expenses for impairments of financial assets and contract assets amounted to € -0.4 million for the first half of 2025 (H1/2024: € 9k).

The net balance of other operating income and expenses stood at € -1.3 million in the first half of 2025 (H1/2024: € 1.0 million). Among other factors, the expenses incurred compared for the currency-related translation of balance sheet items were higher than in the previous year.

Consolidated sales by operating division

€ 000s	H1/2025	H1/2024 ¹	Change
Analyzer systems	34,933	35,795	-2.4% cc -2.2%
Service Parts and Consumables	53,728	52,254	+2.8% cc +3.4%
Development and Services	28,750	23,969	+19.9% cc +20.5%
Other	1,179	673	+75.2% cc +76.8%
Consolidated sales	118,590	112,691	+5.2% cc +5.8%

cc = constant currency

¹ Restated pursuant to IAS 8.

Adjusted EBIT amounted to € 8.5 million in the first half of 2025, compared with € 9.9 million in the previous year. The adjusted EBIT margin therefore amounted to 7.2% and thus fell short of the previous year's figure of 8.8%. This reduction in the margin was chiefly due to the negative currency translation effects arising in the second quarter of 2025. These are included in the other operating income and expenses line item.

Contrasting with the reduction in operating earnings, net financial expenses improved. Overall, adjusted consolidated net income for the first half of 2025 therefore fell only slightly from € 5.6 million to € 5.0 million. The adjusted earnings per share (basic) calculated on this basis amounted to € 0.41 (H1/2024: € 0.46).

To facilitate comparison, the key earnings figures for the first half of 2025 have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and restructuring expenses). A reconciliation of the adjusted figures with those reported in the consolidated statement of comprehensive income is presented in the following tables.

€ 000s	H1/2025	H1/2024 ²
Adjusted EBITDA	16,070	17,426
Adjustments		
• Other ¹	-1,551	-120
EBITDA	14,519	17,306

¹ Including one-off advisory expenses, fees, and restructuring expenses.

² Restated pursuant to IAS 8.

€ 000s	H1/2025	H1/2024 ²
Adjusted EBIT	8,487	9,880
Adjustments		
• PPA amortization	-1,617	-1,871
• Other ¹	-1,551	-120
EBIT	5,319	7,889

¹ Including one-off advisory expenses, fees, and restructuring expenses.

² Restated pursuant to IAS 8.

€ 000s	H1/2025	H1/2024 ²
Adjusted consolidated net income	4,978	5,603
Adjusted earnings per share (basic)	0.41	0.46
Adjustments		
• PPA amortization	-1,617	-1,871
• Other ¹	-1,551	-120
• Taxes on income	792	434
Consolidated net income	2,602	4,046
Earnings per share in € (basic)	0.21	0.33

¹ Including one-off advisory expenses, fees, and restructuring expenses.

² Restated pursuant to IAS 8.

Financial position

The cash flow from operating activities for the first half of 2025 amounted to € -5.8 million, compared with € 17.4 million in the previous year. Alongside the lower level of consolidated net income, this key figure was affected by the significantly higher amount of income taxes paid, as well as by an increase in net working capital.

At € 9.0 million, the outflow of funds from investing activities in the first six months of 2025 was at almost the same level as in the previous year (€ 8.8 million). Of this total, € 3.9 million related to investments in intangible assets (H1/2024: € 4.4 million), while € 5.1 million involved investments in property, plant and equipment (H1/2024: € 4.3 million). The investment ratio (investments in property, plant and equipment and intangible assets as a percentage of sales) amounted to 7.6% in the first six months (H1/2024: 7.8%) and was therefore lower than the corridor of 8.0% to 10.0% targeted for the 2025 financial year as a whole.

The cash flow from financing activities stood at € -12.4 million in the first half of 2025 (H1/2024: € -11.6 million) and comprised net repayments of financial liabilities/loans amounting to € 3.4 million, the dividend of € 7.3 million distributed to shareholders in July 2025, and repayments of lease liabilities amounting to € 1.7 million.

Asset position

Total assets decreased to € 422.4 million as of June 30, 2025 (December 31, 2024: € 445.1 million).

Non-current assets amounted to € 220.3 million as of June 30, 2025 (December 31, 2024: € 221.6 million), with only minor changes in the constituent line items. At € 64.9 million, property, plant and equipment were at almost the same level as at December 31, 2024 (€ 65.1 million). Intangible assets showed moderate changes,

with goodwill falling slightly from € 51.0 million to € 49.1 million due to currency effects while other intangible assets increased slightly from € 62.9 million to € 63.6 million.

Current assets decreased to € 202.1 million as of June 30, 2025 (December 31, 2024: € 223.5 million). This reduction was due above all to changes in cash, while inventories and contract assets in particular showed increases. Cash stood at € 18.7 million as of June 30, 2025 (December 31, 2024: € 47.2 million).

The equity and liabilities side of the balance sheet witnessed changes as of June 30, 2025, with these being due in particular to a reduction in trade payables, which fell from € 18.4 million (December 31, 2024) to € 14.7 million. Current and non-current financial liabilities totaled € 128.7 million at the reporting date (December 31, 2024: € 134.3 million).

Due to the dividend distribution of € 7.3 million in July 2025 and currency-related items within other equity, shareholders' equity fell from € 242.5 million as of December 31, 2024 to € 236.7 million as of June 30, 2025. Contrasting with this reduction, the equity ratio rose to 56.0% and is thus 150 basis points higher than at December 31, 2024 (54.5%).

Macroeconomic and sector-specific framework

Macroeconomic framework¹

In its Economic Outlook published in June 2025, the Organisation for Economic Cooperation and Development (OECD) warns of a deterioration in global economic prospects. Growth was being held back by barriers to trade, more restrictive financing conditions, low levels of trust, and political uncertainties. Global economic growth was expected to decline from 3.3% in 2024 to 2.9% in 2025 and 2026, with the USA, Canada, Mexico, and China being particularly affected by this slowdown. Despite declining commodity prices, inflation remained high in some regions, particularly as a result of increased trading costs.

The OECD stresses the risks of any further fragmentation in trade and the negative impact of this on supply chains, growth, and inflation. These risks were being increased by higher levels of government debt and financial restrictions, above all for low-income countries. By contrast, a reversal of trade restrictions and a peaceful solution of international conflicts could promote growth and trust.

Central banks should remain alert and adjust interest rates in line with developments in inflation and growth. Governments had to place their fiscal policies on a sustainable footing, optimize spending, and maintain government debt at manageable long-term levels. Given the challenges, extensive structural reforms were needed to promote investment, innovation, and productivity and to raise living standards. In particular, greater investment in digital technologies and public infrastructure would be decisive in securing future economic growth.

Given its long-term project and product lifecycles, STRATEC and the decisions its customers take concerning joint development projects are only affected by macroeconomic fluctuations to a limited extent. Having said this, the macroeconomic climate is nevertheless a significant factor for STRATEC's business activity and is therefore extensively factored into the company's assessments and planning.

Sector-specific framework

Based on various estimates, the in-vitro diagnostics (IVD) market will continue to show very healthy rates of sustainable growth and currently has a volume of around USD 80 billion to USD 90 billion².

Consistently aging populations, the increased prevalence of chronic diseases, more frequent occurrence of infectious diseases, and the ever growing significance of more precise treatment (precision medicine) – these are key market growth drivers that are also sustainable. Over and above that, the research being performed on innovative technologies, such as specific biomarkers, will create new opportunities for future market growth.

¹ Source: OECD: Economic Outlook, June 2025

² Source: e.g. MarketsandMarkets: In Vitro Diagnostics Market, March 2024

Report on forecasts and other statements concerning the company's expected development

Global megatrends, such as aging populations and the growing prevalence of chronic and infectious diseases, are leading to a continuous increase in demand for in-vitro diagnostics tests. Not only that: Technological advances resulting in enhanced process sensitivity are making it possible to access new applications in areas such as oncology, neurology, and prenatal medicine. Qualified laboratory staff are rare in many countries, a factor which is additionally boosting demand for highly automated solutions. STRATEC also expects the growing interest and willingness shown by its customers to outsource the design and manufacture of automation solutions to specialist partners to advance further. This is reflected in the market launches executed in recent years and a solid development pipeline. In light of these factors, the growth prospects for the target markets in which the STRATEC Group and its customers operate are still assessed positively.

STRATEC's sales and earnings performance in the first half of 2025 is largely consistent with the assumptions made in the company's intra-year planning for its 2025 financial guidance. As a result, and based on updated planning for the second half, the Board of Management of STRATEC can confirm the guidance provided for the 2025 financial year. STRATEC therefore continues to expect its consolidated sales at constant currency to show growth in a low to medium single-digit percentage range in the 2025 financial year compared with the previous year. A value of around 10.0% to 12.0% is forecast for the adjusted EBIT margin (2024: 13.0%). Here, a significant intra-year increase in earnings contributions relating to Development and Services is forecast for the fourth quarter of 2025 in particular. Furthermore, Systems sales are expected to show significant growth in the second half of the year compared with the first six months of 2025, with corresponding benefits of scale.

Given that the downstream effects of the pandemic have not yet been fully absorbed and in light of geopolitical conflicts, potential tariffs, and trade barriers, STRATEC expects to see continuing increased volatility in its customers' order behavior. As a result, the key sales and earnings figures forecast for 2025 are subject to greater uncertainties than usual.

For the 2025 financial year, STRATEC has budgeted investments in property, plant and equipment and in intangible assets corresponding to a total of 8.0% to 10.0% of sales (2024: 7.1%).

To enable it to realize the wide variety of growth potential harbored by its current deal and development pipeline, STRATEC plans to maintain a stable workforce, or to expand this slightly, in the years ahead.

STRATEC's financial forecast is based on budgets that account for the specific features of its business model, as well as for numerous internal and external factors, and that weight such factors in accordance with their significance. New order figures, our customers' forecasts and their order behavior; and their stocking of service parts play a superordinate role here, as do the numbers of projects in development and negotiation. This forecast does not account for additional opportunities resulting from external growth. Given the long-term nature of its business relationships, macroeconomic developments are of subordinate significance for STRATEC. The macroeconomic factor is therefore weighted less prominently in the company's forecasts.

Opportunity and risk report

The risk management system forms an active part of STRATEC's corporate management and is largely based on three pillars. In the central early warning risk identification system, the risks facing the corporate divisions and the associated business environment are analyzed, evaluated and monitored, with appropriate measures being taken to counter such risks. Furthermore, the risk management system also comprises an internal control system (IKS) and a compliance management system, which additionally ensures compliance with relevant legal and industry-specific requirements.

Risk management covers all of the STRATEC Group's material operating and administrative departments.

Compared with the risks listed in the Group Management Report for the 2024 financial year, from STRATEC's perspective the following principal changes arose as of June 30, 2025.

STRATEC's customers generate a large share of their sales by selling a full package to end customers. As well as diagnostics reagents, this includes service parts and the analyzer systems. As the analyzer systems account for a relatively low share of the price of this full package, the implications of US tariffs for instrument sales are assessed as low. There has nevertheless been a noticeable increase in the degree of uncertainty created by the discussions surrounding these implications, and this has also affected STRATEC's market environment. As a result, the planning of instrument sales also remains exposed to increased uncertainty.

The risk of increased stocks and associated commitment of liquidity continues to apply. Given the level of demand for molecular diagnostics analyzer systems, which is stabilizing but remains notably subdued, it was not yet possible to make any progress in reducing stocks in the first six months of 2025. Close liaison is being maintained in this respect, as is the further stocking of critical components, particularly in areas exposed to the risk of supply bottlenecks due to the availability of rare earths.

New staff hires have alleviated the tight personnel situation in the Finance department since the period in which the 2024 consolidated financial statements were prepared. These have significantly reduced compliance risks concerning the timely preparation of the company's financial statements.

The core focus of STRATEC's strategic financial planning involves ensuring that the operating business is financed and upholding the company's freedom to take entrepreneurial decisions. A syndicated financing facility with a five-year term is due to be agreed before the end of August 2025. This is intended to replace a credit framework agreement with a term until Q1 2027 and bridge financing through to September 2025.

STRATEC expects to continue generating a notable share of its sales in US dollars. It therefore closely monitors movements in the US dollar, which has weakened since the end of 2024. Given this volatility, the company aims to achieve a higher hedging rate for sales denominated in US dollars in future. This may result in increased risks relating to the fair value measurement of hedges in future.

Apart from these risks, STRATEC currently does not see any notable changes compared with the information provided in the Group Management Report on the 2024 financial year.

Details of our risk management system and our company's specific opportunity and risk profile and of our use of financial instruments can be found in the "Opportunities and Risks" section of the 2024 Group Management Report.

CONSOLIDATED BALANCE SHEET

as of June 30, 2025

Assets

€ 000s	06.30.2025	12.31.2024
Non-current assets		
Goodwill	49,145	50,975
Other intangible assets	63,632	62,889
Right-of-use assets	13,604	15,180
Property, plant and equipment	64,939	65,065
Non-current financial assets	3,513	3,472
Non-current contract assets	22,429	20,859
Deferred taxes	3,072	3,116
	220,334	221,556
Current assets		
Inventories	125,114	121,818
Trade receivables	40,357	41,578
Current financial assets	1,988	1,563
Current other receivables and assets	7,441	7,951
Current contract assets	5,993	1,209
Income tax receivables	2,483	2,219
Cash	18,698	47,164
	202,074	223,502
Total assets	422,408	445,058

Shareholders' equity and debt

€ 000s	06.30.2025	12.31.2024
Shareholders' equity		
Share capital	12,158	12,158
Capital reserve	37,536	37,131
Revenue reserves	192,575	197,267
Treasury stock	-35	-35
Other equity	-5,536	-3,988
	236,698	242,533
Non-current debt		
Non-current financial liabilities	95,753	88,695
Current other liabilities	1,189	1,201
Non-current contract liabilities	555	343
Provisions for pensions	5,148	5,338
Provisions	156	190
Deferred taxes	16,023	16,412
	118,824	112,179
Current debt		
Current financial liabilities	32,950	45,565
Trade payables	14,742	18,447
Current other liabilities	10,690	10,369
Current contract liabilities	5,321	7,235
Provisions	621	760
Income tax liabilities	2,562	7,970
	66,886	90,346
Total shareholders' equity and debt	422,408	445,058

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from January 1 to June 30, 2025

€ 000s	01.01. – 06.30.2025	01.01. – 06.30.2024 Retrospectively adjusted ¹
Sales	118,590	112,691
Cost of sales	-86,635	-82,145
Gross profit	31,955	30,546
Research and development expenses	-5,425	-5,560
Sales-related expenses	-6,507	-6,852
General administration expenses	-12,988	-11,260
Income / Expenses from impairment of financial assets and contract assets	-418	9
Other operating expenses	-4,130	-2,577
Other operating income	2,832	3,583
Earnings before interest and taxes (EBIT)	5,319	7,889
Financial income	121	270
Financial expenses	-2,084	-3,003
Other financial result	-62	-1
Net financial result	-2,025	-2,734
Earnings before taxes (EBT)	3,294	5,155
Taxes on income	-692	-1,109
Consolidated net income	2,602	4,046
Items that may be subsequently reclassified to profit or loss:		
Currency translation differences from translation of foreign operations	-1,548	-3,670
Other comprehensive income (OCI)	-1,548	-3,670
Comprehensive income	1,054	376
Basic earnings per share in €	0.21	0.33
No. of shares used as basis (undiluted)	12,155,942	12,155,942
Diluted earnings per share in €	0.21	0.33
No. of shares used as basis (diluted)	12,155,942	12,157,977

¹ Information on the effects of retrospective adjustments or corrections and retrospective changes in accordance with IAS 8 can be obtained from the notes to the consolidated financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS

for the period from January 1 to June 30, 2025

€ 000s	01.01. – 06.30.2025	01.01. – 06.30.2024 Retrospectively adjusted ¹
I. Operations		
Consolidated net income (after taxes)	2,602	4,046
Depreciation and amortization	9,200	9,417
Current income tax expenses	1,208	1,222
Income taxes paid less income taxes received	-6,852	615
Financial income	-121	-270
Financial expenses	2,084	3,003
Interest paid	-2,022	-2,949
Interest received	167	270
Other non-cash expenses	3,650	1,779
Other non-cash income	-1,869	-1,453
Change in net pension provisions through profit or loss	-219	-15
Change in deferred taxes through profit or loss	-517	-113
Profit (-) / loss (+) on disposals of non-current assets	0	-163
Increase (-) / decrease (+) in inventories, trade receivables and other assets	-7,432	5,342
Increase (+) / decrease (-) in trade payables and other liabilities	-5,650	-3,350
Cash flow from operating activities	-5,771	17,381
II. Investments		
Incoming payments from disposals of non-current assets		
• Property, plant and equipment	0	9
Outgoing payments for investments in non-current assets		
• Intangible assets	-3,883	-4,406
• Property, plant and equipment	-5,077	-4,276
• Financial assets	0	-100
Cash flow from investing activities	-8,960	-8,773
III. Financing		
Incoming funds from taking up of financial liabilities	21,429	10,000
Outgoing payments for repayment of financial liabilities	-24,848	-13,323
Outgoing payments for repayment of lease liabilities	-1,700	-1,617
Dividend payments	-7,294	-6,687
Cash flow from financing activities	-12,413	-11,627
IV. Cash-effective change in cash (net balance I – III)	-27,144	-3,019
Cash at start of period	47,164	33,532
Impact of exchange rate movements	-1,322	-352
Cash at end of period	18,698	30,161

¹ Information on the effects of retrospective adjustments or corrections and retrospective changes in accordance with IAS 8 can be obtained from the notes to the consolidated financial statements

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the period from January 1 to June 30, 2024

€ 000s	Share capital	Capital reserve
December 31, 2023 as previously stated	12,158	36,273
Adjustments in accordance with IAS 8		
December 31, 2023 Retrospectively adjusted	12,158	36,273
Equity transactions with owners		
• Dividend payment		
Allocations due to stock option programs		507
Comprehensive income		
June 30, 2024¹	12,158	36,780

¹ Information on the effects of retrospective adjustments or corrections and retrospective changes in accordance with IAS 8 can be obtained from the notes to the consolidated financial statements

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the period from January 1 to June 30, 2025

€ 000s	Share capital	Capital reserve
December 31, 2024	12,158	37,131
Equity transactions with owners		
• Dividend payment		
Allocations due to stock option programs		405
Comprehensive income		
June 30, 2025	12,158	37,536

			Other equity		
	Revenue reserves	Treasury stock	Pension plans	Currency translation	Group equity
	184,100	-35	-881	1,711	233,326
	3,767				3,767
	187,867	-35	-881	1,711	237,093
	-6,687				-6,687
					507
	4,046			-3,670	376
	185,226	-35	-881	-1,959	231,289

			Other equity		
	Revenue reserves	Treasury stock	Pension plans	Currency translation	Group equity
	197,267	-35	-1,521	-2,466	242,534
	-7,294				-7,294
					405
	2,602			-1,548	1,054
	192,575	-35	-1,521	-4,014	236,699

SELECT EXPLANATORY NOTE DISCLOSURES

for the period from January 1 to June 30, 2025

Information about the company

STRATEC SE designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the STRATEC Group (hereinafter also "STRATEC") offers complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance. The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies. Customers gain access to these STRATEC technologies by purchasing products or acquiring licenses.

STRATEC SE, whose legal domicile is at Gewerbestrasse 37, 75217 Birkenfeld, Germany, is a publicly listed corporation under European law and is registered in the Commercial Register in Mannheim, Germany, with the number HRB 732007.

This Half-Year Financial Report was approved for publication by the Board of Management of STRATEC SE on August 19, 2025.

Basis of preparation

Consistent with § 115 (2) in conjunction with § 117 No. 2 of the German Securities Trading Act (WpHG), the Half-Year Financial Report of STRATEC SE comprises interim consolidated financial statements, an interim group management report, and a responsibility statement. The interim consolidated financial statements, which have not been audited, have been prepared in abridged form in accordance with the requirements of IAS 34 (Interim Financial Reporting) and in accordance with those International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), London, and interpretations issued by the

International Financial Reporting Interpretations Committee (IFRS IC) that were valid and endorsed by the EU as of the reporting date and, in the case of the interim group management report, additionally in accordance with the applicable requirements of the German Securities Trading Act (WpHG).

The Half-Year Financial Report has been compiled in thousand euros (€ 000s). Unless otherwise stated the amounts in the notes to the interim consolidated financial statements are denominated in thousand euros (€ 000s). Due to numbers being rounded up or down, individual figures in the consolidated financial statements of STRATEC SE may not add up exactly to the totals stated and percentage figures may not correlate exactly with the absolute figures to which they refer.

Accounting policies applied

Apart from those accounting standards and interpretations requiring mandatory application for the first time in the current financial year and unless indicated otherwise below, the accounting policies applied in the interim consolidated financial statements are consistent with those applied in preparing the consolidated financial statements as of December 31, 2024. A detailed description of the accounting policies was published in the notes to the consolidated financial statements. Reference is made to the information provided in Section "B. Accounting policies applied" in the 2024 Annual Report.

STRATEC has not made premature application of new or amended accounting standards and interpretations that have already been published but do not yet require mandatory application.

The following accounting standards and interpretations require mandatory application for the first time in the current financial year:

Standard	Title	Effective date ¹	EU endorsement
New and amended standards and interpretations			
IAS 21	Amendments: Lack of Exchangeability	01.01.2025	11.12.2024

¹ For companies like STRATEC whose financial year corresponds to the calendar year

The application of these standards and interpretations in the current financial year is consistent with the respective transition requirements. Unless explicitly required by individual standards and interpretations and explained separately below, the respective requirements have generally been applied retrospectively, i.e. the information has been presented as if the new accounting methods had always been applied in the past. In these cases – and where called for by the respective standard – the comparative figures have been adjusted accordingly.

Impact of restatements, corrections, and retrospective changes made to the consolidated financial statements as of December 31, 2024 pursuant to IAS 8 (Accounting Policies, Changes in Accounting Estimates and Errors) on the present Half-Year Financial Report

The consolidated financial statements as of December 31, 2024 included corrections made to the prior year's figures. Information about the impact of these restatements, corrections, and retrospective changes pursuant to IAS 8 (Accounting Policies, Changes in Accounting Estimates and Errors) on STRATEC's consolidated financial statements can be found in the notes to the consolidated financial statements for the 2024 financial year.

Continuation of the restatements and corrections made in the notes to the consolidated financial statements for the 2024 financial year led to amendments impacting on earnings in the first half of 2024 and on the disclosures made in the interim consolidated financial statements for the period from January 1, 2024 to June 30, 2024. The impact of this continuation on STRATEC's interim consolidated financial statements for the period from January 1, 2024 to June 30, 2024 is presented below. The corresponding disclosures in the notes to the interim consolidated financial statements have been amended accordingly.

The impact of the aforementioned continuation of restatements and corrections on the **consolidated statement of comprehensive income in the interim consolidated financial statements for the period from January 1, 2024 to June 30, 2024** can be summarized as follows. To enhance clarity, only those items affected by the adjustments have been presented (in € 000s):

Item	06.30.2024 (after adjustment)	Adjustments	06.30.2024 (reported)
Sales	112,691	-6,385	119,076
Cost of sales	-82,145	6,550	-88,695
Taxes on income	-1,109	-41	-1,068
Consolidated net income	4,046	124	3,922

Based on the amended consolidated net income, the following adjustments arose in the **consolidated cash flow statement in the interim consolidated financial statements for the period from January 1, 2024 to June 30, 2024**. To enhance clarity, only those items affected by the adjustments have been presented (in € 000s):

Item	06.30.2024 (after adjustment)	Adjustments	06.30.2024 (reported)
Consolidated net income (after taxes)	4,046	124	3,922
Depreciation and amortization	9,417	-57	9,474
Change in deferred taxes through profit or loss	-113	41	-154
Increase (-) / decrease (+) in inventories, trade receivables, and other assets	5,342	-7,460	12,802
Increase (+) / decrease (-) in trade payables and other liabilities	-3,350	7,352	-10,702
Cash flow from operating activities	17,381	0	17,381

Based on the amended consolidated net income, the following adjustments arose in the **consolidated statement of changes in equity in the interim consolidated financial statements for the period from January 1, 2024 to June 30, 2024**. To enhance clarity, only those items affected by the adjustments have been presented (in € 000s):

	06.30.2024 Revenue reserves	06.30.2024 Group equity
IAS 8 adjustments	-124	-124

Impairment tests

STRATEC performs impairment tests pursuant to IAS 36 (Impairment of Assets) on goodwill and other intangible assets with unlimited or indefinite useful lives, as well as on intangible assets not yet ready for use, at least once a year. Furthermore, impairment tests pursuant to IAS 36 (Impairment of Assets) are performed when specific indications of impairment arise on the basis of external and internal sources of information.

Segment disclosures

STRATEC is a single-segment entity within the meaning of IFRS 8 (Operating Segments), as its business activities focus on the design and manufacture of automation solutions for partners in the field of in-vitro diagnostics. Internal reporting focuses on key value drivers such as technologies and systems related to these automation solutions. Accordingly, STRATEC is managed as a single reporting unit by its chief operating decision makers, who make decisions and allocate resources at this level.

The following is a summary of the key figures from the consolidated statement of consolidated income:

Summary of key figures from the consolidated statement of comprehensive income	01.01.– 06.30.2025	01.01.– 06.30.2024	Change
Sales (€ 000s)	118,590	112,691	+5.2% (cc: +5.8%)
Adjusted EBITDA (€ 000s)	16,070	17,426	-7.8%
Adjusted EBITDA margin (%)	13.6	15.5	-190 bps
Adjusted EBIT (€ 000s)	8,487	9,880	-14.1%
Adjusted EBIT margin (%)	7.2	8.8	-160 bps
Adjusted consolidated net income (€ 000s)	4,978	5,603	-11.2%
Adjusted earnings per share (€)	0.41	0.46	-10.9%
Earnings per share (€)	0.21	0.33	-36.4%

bps = basis points
cc = constant currency

To facilitate comparison, the key earnings figures for the period under report have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items. The reconciliation of adjusted operating earnings before depreciation and amortization (EBITDA) with the earnings before taxes (EBT) reported in the consolidated statement of comprehensive income is as follows:

€ 000s	01.01.– 06.30.2025	01.01.– 06.30.2024
Adjusted operating earnings (EBIT)	8,487	9,880
PPA amortization	-1,617	-1,871
Advisory expenses and fees	-1,185	-53
One-off personnel expenses	-366	-67
Operating earnings (EBIT)	5,319	7,889
Net financial expenses	-2,025	-2,734
Earnings before taxes (EBT)	3,294	5,155

Scope of consolidation

In accordance with the requirements of IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of STRATEC SE (parent company) basically include all companies controlled by STRATEC SE (subsidiaries). The scope of consolidation has not changed compared with December 31, 2024. Specifically, alongside STRATEC SE these comprise the following subsidiaries:

Company	Domicile	Shareholding %	
		06.30.2025	12.31.2024
Germany			
STRATEC Capital GmbH	Birkenfeld, Germany	100%	100%
STRATEC PS Holding GmbH	Birkenfeld, Germany	100%	100%
European Union			
STRATEC Biomedical S.R.L.	Cluj-Napoca, Romania	100%	100%
STRATEC Consumables GmbH	Anif, Austria	100%	100%
RE Medical Analyzers Luxembourg 2 S.à r.l.	Luxembourg, Luxembourg	100%	100%
Diatron Medicinai Instrumentumok Laboratóriumi Diagnosztikai Fejlesztő-Gyártó Zrt	Budapest, Hungary	100%	100%
Mod-n-More Kft.	Budapest, Hungary	100%	100%
Other			
STRATEC Switzerland AG	Beringen, Switzerland	100%	100%
STRATEC Biomedical USA, Inc.	Medley, USA	100%	100%
Medical Analyzers Holding GmbH	Zug, Switzerland	100%	100%
STRATEC Biomedical Inc.	Medley, USA	100%	100%
Diatron (US), Inc.	Medley, USA	100%	100%
Natech Plastics, Inc.	Ronkonkoma, USA	100%	100%
Diatron MI APAC Private Limited	New Delhi, India	100%	100%
STRATEC Biomedical (Taicang) Co. Ltd., Taicang, China	Taicang, China	100%	100%
STRATEC Biomedical Ltd. Shanghai	Shanghai, China	100%	100%

Sales

The sales generated from contracts with customers in the respective periods are structured as follows:

€ 000s	01.01.– 06.30.2025	01.01.– 06.30.2024
Type of goods or services		
Analyzer systems	34,933	35,795
Service parts and consumables	53,728	52,254
Development and services	28,750	23,969
Other	1,179	673
Total	118,590	112,691
Geographical regions		
Germany	12,843	11,656
European Union	49,108	37,462
Other	56,639	63,573
• of which USA	49,696	51,521
Total	118,590	112,691
Time at which sales are recognized		
Recognized at a point in time	111,041	105,563
Recognized over time	7,549	7,128
Total	118,590	112,691

Research and development expenses

Research and development expenses not meeting the criteria for capitalization pursuant to IAS 38 (Intangible Assets) totaled € 5.4 million in the first six months of the 2025 financial year (previous year: € 5.6 million) and mainly involved personnel expenses and cost of materials. Overall, STRATEC invested a total of € 29.0 million in research and development in the first six months of the 2025 financial year (previous year: € 28.1 million).

Intangible assets, right-of-use assets, and property, plant and equipment

STRATEC invested a total of € 8,960k in intangible assets and property, plant and equipment in the first six months of the 2025 financial year (previous year: € 8,682k).

Investments in intangible assets mainly relate to the capitalization of development expenses, while investments in property, plant and equipment chiefly involve the acquisition of building fittings, machinery, tools, and test materials.

Of intangible assets, € 38,622k (12.31.2024: € 38,016k) are located in the country of origin of STRATEC SE and € 74,155k (12.31.2024: € 75,848k) in third countries. The third countries with a material volume of intangible assets are Hungary (€ 33,827k; 12.31.2024: € 31,257k), the USA (€ 25,092k; 12.31.2024: € 28,650k), and Austria (€ 13,155k; 12.31.2024: € 13,673k).

Of right-of-use assets, € 635k (12.31.2024: € 666k) are located in the country of origin of STRATEC SE and € 12,969k (12.31.2024: € 14,514k) in third countries. The third countries with a material volume of right-of-use assets are Hungary (€ 5,413k; 12.31.2024: € 5,638k), the USA (€ 3,181k; 12.31.2024: € 3,888k), and Austria (€ 3,856k; 12.31.2024: € 4,347k).

Of property, plant and equipment, € 42,069k (12.31.2024: € 41,698k) are located in the country of origin of STRATEC SE and € 22,870k (12.31.2024: € 23,367k) in third countries. The third countries with a material volume of property, plant and equipment are Switzerland (€ 7,143k; 12.31.2024: € 7,332k), the USA (€ 4,054k; 12.31.2024: € 4,565k), and Austria (€ 5,685k; 12.31.2024: € 5,256k).

Inventories

Inventories are structured as follows:

	06.30.2025 € 000s	12.31.2024 € 000s
Raw materials and supplies	96,948	95,858
Unfinished products	8,936	8,569
Finished products	14,483	11,230
Merchandise	959	1,967
Prepayments made	3,788	4,194
Total	125,114	121,818

Financial instruments

The table below presents the carrying amounts for each individual measurement category and the fair values for each individual measurement class of financial instruments pursuant to IFRS 9 (Financial Instruments) and reconciles these with the respective balance sheet items. No offsetting was performed within the financial line items as of the balance sheet date, neither was there any netting potential.

Abbreviations for measurement categories:

AC Measured at (amortized) cost

FVTPL Measured at fair value through profit or loss

06.30.2025 (12.31.2024)	IFRS 9 category	Carrying amount € 000s	Amortized cost € 000s	of which Level 1 € 000s	Fair value of which Level 2 € 000s	of which Level 3 € 000s	Not attribut- able to any measurement category € 000s	Total € 000s
Non-current assets								
Financial assets								
• Amortized cost	AC	3,513 (3,472)	3,513 (3,472)					3,513 (3,472)
Current assets								
Trade receivables	AC	40,357 (41,578)	40,357 (41,578)					40,357 (41,578)
Financial assets								
• Amortized cost	AC	837 (832)	837 (832)					837 (832)
• Fair value through profit or loss	FVTPL	1,151 (731)		670 (731)	481 (0)			1,151 (731)
Cash	AC	18,698 (47,164)	18,698 (47,164)					18,698 (47,164)
Total financial assets								
of which amortized cost	AC		63,405 (93,047)	0 (0)	0 (0)	0 (0)		63,405 (93,047)
of which fair value through profit or loss	FVTPL		0 (0)	670 (731)	481 (0)	0 (0)		1,151 (731)

06.30.2025 (12.31.2024)	IFRS 9 category	Carrying amount € 000s	Amortized cost € 000s	Fair value			Not attribut- able to any measurement category € 000s	Total € 000s
				of which Level 1 € 000s	of which Level 2 € 000s	of which Level 3 € 000s		
Non-current debt								
Financial liabilities								
• Amortized cost	AC	95,753 (88,695)	85,251 (76,448)				10,502 (12,246)	95,753 (88,694)
Current debt								
Financial liabilities								
• Amortized cost	AC	32,951 (45,304)	29,477 (41,972)				3,474 (3,331)	32,951 (45,303)
• Fair value through profit or loss	FVTPL	0 (262)			0 (262)			0 (262)
Trade payables	AC	14,742 (18,447)	14,742 (18,447)					14,742 (18,447)
Total financial debt								
of which amortized cost	AC		129,470 (136,867)	0 (0)	0 (0)	0 (0)		129,470 (136,867)
of which fair value through profit or loss	FVTPL		0 (0)	0 (0)	0 (262)	0 (0)		0 (262)

Fair value hierarchy

No items were reclassified within the three input factor levels in the period from January 1 to June 30, 2025 or in the comparative period. Any reclassifications into or out of fair value hierarchy levels are performed at the end of the reporting period. The financial assets allocated to Level 1 involve shares in listed companies, which have been measured at the closing price on the stock market with the highest trading volumes as of the balance sheet date. The financial assets and liabilities allocated to Level 2 involve forward exchange transactions to hedge currency risks.

The fair value of financial instruments is determined as the present value of future cash inflows or outflows. Discounting is based on a market interest rate with a congruent term and risk structure. For financial instruments measured at fair value, a quoted price in an active market is used, if available. For short-term financial assets and liabilities not measured at fair value, the fair values approximate to their carrying amounts due to the short remaining terms. For non-current other financial assets measured at amortized cost, the carrying amount also approximates to fair value due to deposits with banks and the correspondingly very low credit risk. The fair value of non-current financial liabilities measured at amortized cost amounts to € 81,022k (12.31.2024: € 72,368k) and is allocated to Level 3.

Financial liabilities

Financial liabilities include liabilities to banks of € 111,387k (12.31.2024: € 114,957k) and lease liabilities of € 13,976k (12.31.2024: € 15,577k).

Of the liabilities to banks, € 63.4 million (12.31.2024: € 52.0 million) involve liabilities in connection with a master credit facility with a revolving credit line of up to € 75.0 million (12.31.2024: € 75.0 million) that was concluded with four banks and has a term through to January 22, 2027. Furthermore, € 24.0 million (12.31.2024: € 36.0 million) relate to liabilities in connection with a master credit facility with a revolving credit line of up to € 50.0 million (12.31.2024: € 50.0 million) that was concluded with an existing bank to finance the acquisition of the Natech Group and further investment opportunities. This has a term through to September 19, 2025. The interest payable on amounts effectively drawn down from the master credit facilities is based on customary market reference rates plus a margin. Non-compliance with specific financial key figures would result in the margin being increased by a premium. A commitment fee is payable on amounts not drawn down from the master credit facilities. Of the liabilities to banks, € 87.4 million have floating interest rates (12.31.2024: € 88.0 million).

For the predominant share of financial liabilities to banks (06.30.2025: € 102,865k; 12.31.2024: € 105,867k), the relevant financing contracts include agreements concerning compliance with specific financial key figures (covenants). In particular, these involve the debt/equity ratio (06.30.2025: 3.5; 12.31.2024: 4.0) and the equity ratio (06.30.2025: 30%; 12.31.2024: 30%). The financial covenants have to be calculated at the end of each quarter, half-year, and full year and communicated to the lending banks. Furthermore, the company is required to fulfill informational and reporting obligations by submitting audited consolidated financial statements and audited separate financial statements by April 30 each year. Any failure to comply with the aforementioned financial covenants or to meet the informational and reporting obligations would entitle the banks to terminate the facilities. Moreover, the company has entered into general obligations involving restrictions on assets and provisos concerning further borrowing.

Other liabilities

Other liabilities include the total obligation of € 414k (12.31.2024: € 335k) stated for expected payments in connection with the stock appreciation rights (SARs) granted. In the period under report, expenses of € 79k were recognized through profit or loss for cash-settled share-based payments (previous year: € 750k).

The fair value of stock appreciation rights (SARs) developed as follows:

Stock appreciation rights (SARs): Model parameters	Tranche 1/2025	Tranche 1/2024	Tranche 1/2023	Tranche 1/2022	Tranche 1/2021
Issue date	02.10.2025	01.19.2024	01.23.2023	01.25.2022	03.08.2021
Average share price on issue date	€ 34.85	€ 40.50	€ 84.70	€ 114.40	€ 107.20
Term					
• Overall term	84.0 months	84.0 months	84.0 months	60.0 months	60.0 months
• Remaining term as of 06.30.	77.2 months	66.7 months	54.7 months	18.8 months	8.3 months
Minimum waiting period					
• Overall term	48.0 months	48.0 months	48.0 months	24.0 months	24.0 months
• Remaining term as of 06.30.	41.2 months	30.7 months	18.7 months	0.0 months	0.0 months
Share price at measurement date	€ 26.20	€ 26.20	€ 26.20	€ 26.20	€ 26.20
Fair value on issue date	€ 4.52	€ 12.60	€ 31.35	€ 37.45	€ 38.05
Fair value as of 06.30.2025	€ 5.20	€ 4.22	€ 0.89	€ 0.06	€ 0.00

The development in the number of stock appreciation rights (SARs) is presented below:

Number of rights	Total at 01.01.2025	Granted	Exercised / lapsed / forfeited	Total at 06.30.2025	of which exercisable
Tranche I/2021	22,500	0	0	22,500	0
Tranche I/2022	22,500	0	0	22,500	0
Tranche I/2023	38,370	0	0	38,370	0
Tranche I/2024	40,340	0	0	40,340	0
Tranche I/2025	0	40,000	0	40,000	0
Total	123,710	40,000	0	163,710	0

Risk management activities

STRATEC's assets, liabilities and future activities are subject to liquidity risks, default risks, and market risks resulting from changes in exchange rates, interest rates, and stock market prices.

The gross carrying amounts of trade receivables by time band and the allowances stated for "expected credit losses" are structured as follows:

€ 000s	Gross carrying amount	Gross carry amounts of non-impaired creditworthiness	Gross carrying amounts of impaired creditworthiness
06.30.2025	43,669	37,082	6,587
12.31.2024	44,471	38,124	6,347

STRATEC had concluded hedging transactions as of June 30, 2025. These involve currency futures intended to hedge future cash flows from sales in USD. No use was made of the hedge accounting provisions of IFRS 9 (Financial Instruments).

Shareholders' equity

The development in shareholders' equity at STRATEC and dividends paid is presented in the consolidated statement of changes in equity. The number of ordinary shares issued by STRATEC SE as of June 30, 2025 amounts to 12,157,841 (previous year: 12,157,841; 12.31.2024: 12,157,841). All shares are fully paid in and are registered shares.

Treasury stock holdings

The company owned 1,899 treasury stock shares at the interim balance sheet date. This corresponds to a prorated amount of € 1,899.00 of the company's share capital and to a 0.02% share of its equity.

Stock option programs

The company had three (previous year: three) stock option programs (equity-settled share-based payment) as of June 30, 2025.

The following options schedule provides a summary of the development in stock option rights in the period under report:

Stock option rights	Board of Management No. of options	Employees No. of options	Total No. of options
Outstanding on 01.01.2025			
• of which exercisable	29,557	196,729	226,286
	0	0	0
Granted	0	26,200	26,200
Exercised	0	0	0
Lapsed	0	0	0
Forfeited	0	0	0
Outstanding on 06.30.2025			
• of which exercisable	29,557	222,929	252,486
	0	0	0

Components of other comprehensive income

The other equity of € -5,536k (previous year: € -2,840k; 12.31.2024: € -3,988k) includes the currency translation reserve, cumulative actuarial gains and losses from the remeasurement of pensions, and the resultant deferred taxes.

The currency translation reserve of € -4,014k recognized as of the reporting date (previous year: € -1,959k; 12.31.2024: € -2,466k) mainly comprises currency differences arising upon the translation of the separate financial statements of companies whose functional currency is not the euro and from the translation within equity of group-internal net investments as of the reporting date. The change in this item is recognized in the "Currency translation differences from translation of foreign business operations" line item in the consolidated statement of comprehensive income.

Select related party disclosures

In addition to the companies included in the interim consolidated financial statements, STRATEC SE has relationships with related companies and individuals (related parties). These include business relationships with members of the Supervisory Board and Board of Management of STRATEC SE and their close relatives.

As of June 30, 2025, STRATEC reported outstanding balances due to member of the Board of Management. These amounted to € 2,315k in connection with profit participation (12.31.2024: € 1,855k), to € 3,373k in connection with the company pension scheme (12.31.2024: € 3,234k), and to € 121k in connection with a retrospective prohibition on competition (12.31.2024: € 484k).

Employees

Including temporary employees and trainees, STRATEC had a total of 1,416 employees as of June 30, 2025 (previous year: 1,464; 12.31.2024: 1,450).

Major events after the interim balance sheet date

No events of particular significance which can be expected to materially influence the Group's earnings, financial, or asset position have occurred since the interim balance sheet date.

Responsibility statement

We hereby affirm that, to the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group consistent with the principles of proper accounting, and the interim group management report includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

Birkenfeld, August 19, 2025

STRATEC SE

The Board of Management


Marcus Wolfinger


Dr. Claus Vielsack


Dr. Georg Bauer

FINANCIAL CALENDAR

08 08.19.2025 Half-Year Financial Report H1 2025	11 11.07.2025 Quarterly Statement 9M 2025	11 11.25.2025 German Equity Forum (Analyst Conference)
---	--	---

Subject to amendment.

Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

IMPRINT AND CONTACT

Published by

STRATEC SE

Gewerbestr. 37

75217 Birkenfeld

Germany

Phone: +49 7082 7916-0

info@stratec.com

www.stratec.com

Head of Investor Relations,

Sustainability & Corporate Communications

Jan Keppeler

Phone: +49 7082 7916-6515

j.keppeler@stratec.com

Notice

Forward-looking statements involve risks: This half-year financial report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This half-year financial report contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this half-year financial report on account of mathematical rounding up or down in the course of addition.

This half-year financial report is available in both German and English. Both versions can be downloaded from the company's website at www.stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.